Welcome to the latest issue of EMJ Gastroenterology, which outlines key advances in the field. Featured articles include a case report on medullary carcinoma of the pancreas and a review of the challenges in inflammatory bowel disease management during the COVID-19 pandemic in resource-limited settings. Our independent review of United European Gastroenterology (UEG) Week 2022 is also not to be missed!
Latest articlesAll articles
Gastric Pouch Gastrointestinal Stromal Tumour Post-Roux-en-Y Gastric Bypass: A First Reported Case
Gastric gastrointestinal stromal tumour is an extremely rare condition to occur after bariatric surgery. To the authors’ knowledge, only two cases of gastric gastrointestinal stromal tumours after Roux-en-Y gastric bypass have been reported in the medical literature, both occurring in the excluded gastric remnant. Herein, the authors report the third case of gastric gastrointestinal stromal tumour post-Roux-en-Y gastric bypass, and the first case to occur in the gastric pouch, which was managed surgically by laparoscopic resection. From here, combining the observations of clinicians treating and following up patients post-bariatric surgery in an international database will be beneficial to patients, and aid in development of surveillance guidelines.
The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance
The over-production of TNF-α can lead to chronic inflammation and organ damage in immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), axial spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Anti-TNF therapy is generally considered to be an effective, well-tolerated treatment option for the management of chronic inflammation in these conditions.